Cerebrospinal Fluid Tau Protein and Periventricular White Matter Lesions in Patients with Mild Cognitive Impairment: Implications for 2 Major Pathways

Archives of Neurology

Volumn 61, Issue 5, 2004, Pages 716-720

  Maruyama, Masahiro ^a   Matsui, Toshifumi ^a   Tanji, Haruko ^a   Nemoto, Miyako ^a   Tomita, Naoki ^a   Ootsuki, Mari ^a   Arai, Hiroyuki ^a   Sasaki, Hidetada ^a  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; BIOLOGICAL MARKER; HOMOCYSTEINE; TAU PROTEIN;

AGE; AGED; ALZHEIMER DISEASE; AMNESIA; ARTICLE; BRAIN INFARCTION; BRAIN INJURY; BRAIN VENTRICLE; COGNITIVE DEFECT; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FOLLOW UP; GENOTYPE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTPATIENT DEPARTMENT; POPULATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN CEREBROSPINAL FLUID LEVEL; RISK; RISK FACTOR; SECONDARY PREVENTION; WHITE MATTER;

AGED; ALZHEIMER DISEASE; APOLIPOPROTEINS E; BIOLOGICAL MARKERS; BRAIN; COGNITION DISORDERS; DEMENTIA; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HOMOCYSTEINE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; NEUROPSYCHOLOGICAL TESTS; PROSPECTIVE STUDIES; RISK FACTORS; TAU PROTEINS;

EID: 2442560530     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.61.5.716     Document Type: Article

References (23)

1. DeCarli C. Mild cognitive impairment: prevalence, prognosis, aetiology, and treatment. Lancet Neurol. 2003;2:15-21.
2. Petersen RC. Mild cognitive impairment clinical trials. Nat Rev Drug Discov. 2003;2:646-653.
3. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56:303-308.
4. DeCarli C, Miller BL, Swan CE, Reed T, Wolf PA, Carmelli D. Cerebrovascular and brain morphologic correlates of mild cognitive impairment in the National Heart, Lung, and Blood Institute Twin Study. Arch Neurol. 2001;58:643-647.
5. Kivipelto M, Helkala E-L, Hanninen T, et al. Midlife vascular risk factors and late-life mild cognitive impairment. Neurology. 2001;56:1683-1689.
6. 1-42 levels in the mild cognitive impairment stage of Alzheimer's disease. Exp Neurol. 2001;172:433-436.
7. Sugishita M, Omura K. Learning Chinese characters may improve visual recall. Percept Mot Skills. 2001;93:579-594.
8. Petersen RC, Doody R, Kurz A, et al. Current concepts in mild cognitive impairment. Arch Neurol. 2001;58:1985-1992.
9. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-944.
10. Yao H, Yuzuriha T, Koga H, et al. Decreased plasma tryptophan associated with deep white matter lesions in elderly subjects. J Neurol Neurosurg Psychiatry. 1999;66:100-103.
11. Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA. MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. AJR Am J Roentgenol. 1987;149:351-356.
12. Wenham PR, Price WH, Blandell G. Apolipoprotein E genotyping by one-stage PCR [letter]. Lancet. 1991;337:1158-1159.
13. Arai H, Terajima M, Miura M, et al. Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer's disease. Ann Neurol. 1995;38:649-652.
14. Maruyama M, Arai H, Ootsuki M, et al. Biomarkers in subjects with amnestic mild cognitive impairment [letter]. J Am Geriatr Soc. 2003;51:1671-1672.
15. Matsui T, Arai H, Yuzuriha T, et al. Elevated plasma homocysteine levels and a risk for silent brain infarction in elderly people. Stroke. 2001;32:1116-1119.
16. Arai H, Ishiguro K, Ohno H, et al. CSF phosphorylated tau protein and mild cognitive impairment a prospective study. Exp Neurol. 2000;166:201-203.
17. Palmer K, Wang H-X, Backman L, Winblad B, Fratiglioni L. Differential evolution of cognitive impairment in nondemented older persons: results from the Kungsholmen Project. Am J Psychiatry. 2002;159:436-442.
18. Wahlund LO, Pihlstrand E, Jonhagen ME. Mild cognitive impairment experience from a memory clinic. Acta Neurol Scand Suppl. 2003;179:21-24.
19. Mitchell TW, Mufson EJ, Schneider JA, et al. Parahippocampal tau pathology in healthy aging, mild cognitive impairment, and early Alzheimer's disease. Ann Neurol. 2002;51:182-189.
20. Guillozet AL, Weintraub S, Mash DC, Mesulam MM. Neurofibrillary tangles, amyloid, and memory in aging and mild cognitive impairment. Arch Neurol. 2003;60:729-736.
21. Riemenschneider M, Lautenschlager N, Wagenpfeil S, Diehl J, Drzezga A, Kurz A. Cerebrospinal fluid tau and β-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment. Arch Neurol. 2002;59:1729-1734.
22. Fazekas F, Schmidt R, Kleinert R, Kapeller P, Roob G, Flooh E. Pathologic correlates of incidental MRI white matter signal hyperintensities. Neurology. 1993;43:1683-1689.
23. de Leeuw F-E, de Groot JC, Oudkerk M, et al. Hypertension and cerebral white matter lesions in a prospective cohort study. Brain. 2002;125:765-772.